AIS Healthcare’s Acquisition of Hunt Valley PharmaLAB

AIS Healthcare's Acquisition of Hunt Valley PharmaLAB

Sheppard, Mullin, Richter & Hampton LLP represented Advanced Infusion Solutions (AIS) in the acquisition.

AIS Healthcare has announced the acquisition of Hunt Valley PharmaLAB, a 503A compounding pharmacy focused on ophthalmology medications. Already the leading targeted drug delivery (TDD) and infusion care provider, AIS Healthcare will now be able to provide high-quality, custom ophthalmology prescriptions to patients across the country.

Hunt Valley provides patient-specific medications for patients undergoing eye surgery or suffering from chronic and complex conditions, such as dry eye. Based in Hunt Valley, MD, the pharmacy currently serves more than 6,700 patients in 15 states. Using Hunt Valley’s existing pharmacy and the new state-of-the-art facility in Dallas, Texas, AIS Healthcare will produce ophthalmic medications for an expanded number of patients.

In its new ophthalmology operations, AIS Healthcare will continue to exceed requirements and expectations for quality and sterility. From compliance procedures that go above and beyond industry standards to finding new ways to put quality at the forefront throughout the compounding process, AIS Healthcare will keep doing more to put patient safety first.

As the leading provider of targeted drug delivery (TDD), infusion care and ophthalmic solutions, AIS Healthcare is committed to doing more of what matters.

The Sheppard Mullin team, led by partner Mike McKinnon (Picture), included partners Frank Dworak and Allison Fulton; and associates Roy Fox, Jane Chen Kane and Allen Babajanian.

Involved fees earner: Allen Babajanian – Sheppard Mullin; Frank Dworak – Sheppard Mullin; Roy Fox – Sheppard Mullin; Allison Fulton – Sheppard Mullin; Michael McKinnon – Sheppard Mullin;

Law Firms: Sheppard Mullin;

Clients: Advanced Infusion Solutions (AIS);


Author: Ambrogio Visconti